Samantha Richardson, NP
Nurse Practitioner · Bastian, VANPI 1063039378
Payments from drug & device makers
Across 160 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$805
- Corcept Therapeutics$264
- Amneal Pharmaceuticals LLC$224
- AstraZeneca$211
- Exact Sciences$132
- Bayer$129
- plus $909 from 23 others
What the payments were for
- Food & beverage$2,675100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $805 |
| Corcept Therapeutics | 18 | $264 |
| Amneal Pharmaceuticals LLC | 13 | $224 |
| AstraZeneca(2 entities) | 10 | $211 |
| Exact Sciences | 7 | $132 |
| Bayer | 8 | $129 |
| AbbVie | 4 | $92 |
| Antares Pharma, Inc. | 6 | $91 |
| Lilly USA, LLC | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 4 | $68 |
| Radius Health, Inc. | 3 | $66 |
| Amgen | 3 | $57 |
| Amryt Pharma Holdings Ltd | 3 | $52 |
| Boehringer Ingelheim | 2 | $46 |
| Endo Pharmaceuticals Inc. | 2 | $45 |
| Insulet Corporation | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Merck | 2 | $30 |
| IBSA Pharma Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
How this compares
$2,675 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 144 | $178,019 |
| OzempicSemaglutide | 124 | $161,377 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $61,270 |
| FarxigaDapagliflozin Propanediol | 71 | $59,809 |
| JardianceEmpagliflozin | 70 | $58,921 |
| TrulicityDulaglutide | 45 | $57,311 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $37,217 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $18,266 |
| Novolog FlexpenInsulin Aspart | 25 | $10,861 |
| JanuviaSitagliptin Phosphate | 16 | $10,160 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $5,706 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,609 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,732 |
| SynthroidLevothyroxine Sodium | 14 | $1,223 |
| Levothyroxine Sodium | 48 | $516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $71 | $235,331189 claims |
| Novo NordiskOzempic | $805 | $161,377124 claims |
| AstraZenecaFarxiga | $211 | $59,80971 claims |
| Boehringer IngelheimJardiance | $46 | $58,92170 claims |
| MerckJanuvia | $30 | $10,16016 claims |
| AbbVieSynthroid | $92 | $1,22314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $224 | $51648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Bastian
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Sasha LeeVirginia Beach$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.